Which company manufactures gaffetuzumab?

Glofitumab (Glofitamab) is developed and produced by Roche Pharma, a famous Swiss pharmaceutical company. Roche Pharmaceuticals was founded in 1896 and is headquartered in Basel, Switzerland. It is one of the world's leading biopharmaceutical companies. With its strong scientific research strength and innovative technology, Roche provides a variety of innovative drugs for the treatment of diseases around the world. Especially in the field of cancer treatment, Roche's drugs have been widely used.

Graftuzumab is a new type of immunotherapy drug that belongs to the class of bispecific antibody drugs. It can simultaneously target CD20 and CD3, which are located on the surface of B cells and T cells respectively. Through this dual-targeting effect, gaffetuzumab can effectively activate the patient's immune system, allowing immune cells to recognize and destroy tumor cells, thereby effectively treating non-Hodgkin's lymphoma and other related cancers.

Roche's success in cancer immunotherapy can be traced to several major innovations, including the development of anti-tumor drugs such as Herceptin. As a leader in the global pharmaceutical industry, Roche continues to promote the advancement of oncology treatments through technological innovation and clinical research. The development of gaffetuzumab is not only an important breakthrough for the company in the field of cancer immunotherapy, but also provides new treatment options for clinicians and patients.

Through close cooperation with multiple scientific research institutions and clinical experts around the world, Roche Pharmaceuticals is committed to improving the effectiveness of cancer treatment and the quality of life of patients through innovative drugs. The launch of gaffetuzumab is one of the results of this effort, providing a new treatment option, especially for patients with relapsed or refractory large B-cell lymphoma (DLBCL) who have failed traditional treatments. As an important force in the global pharmaceutical industry, Roche will continue to promote the research and development of cancer immunotherapy drugs in order to bring better treatment options and survival opportunities to patients around the world.

Reference materials:https://www.drugs.com/glofitamab.html